Startseite>>Signaling Pathways>> PROTAC>> E3 Ligase Ligand-Linker Conjugate>>Thalidomide-PEG5-COOH

Thalidomide-PEG5-COOH

Katalog-Nr.GC62226

Thalidomide-PEG5-COOH ist ein synthetisiertes E3-Ligase-Ligand-Linker-Konjugat, das den auf Thalidomid basierenden Cereblon-Liganden und einen in der PROTAC-Technologie verwendeten Linker enthÄlt.

Products are for research use only. Not for human use. We do not sell to patients.

Thalidomide-PEG5-COOH Chemische Struktur

Größe Preis Lagerbestand Menge
50 mg
506,00 $
Auf Lager
100 mg
810,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com


Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Thalidomide-PEG5-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology[1].

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].

[1]. Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine. Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11.
[2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.

Bewertungen

Review for Thalidomide-PEG5-COOH

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Thalidomide-PEG5-COOH

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.